I D
× COMMENTARYCOVER STORYIN THE NEWSCHEMENTATOR + Show More BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORTFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILESOLIDS PROCESSINGENGINEERING PRACTICEENVIRONMENTAL MANAGEREQUIPMENT & SERVICESFOCUS
Focus on Valves
    A new motorized control valve for the semiconductor…
NEW PRODUCTS + Show More

Comment Business & Economics

Catalent extends commercial spray-drying capacity in Europe

By Scott Jenkins |

 

Catalent, Inc. (Somerset, N.J.; www.catalent.com), a leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, U.K. facility.

This agreement immediately extends Catalent’s global spray drying offering by making available to Catalent and Catalent’s customers the dedicated use of the existing Niro PSD2 and PSD4 spray driers at the facility. These spray dryers are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations as well as a secondary vacuum dryer. Catalent is now able to offer spray drying solutions from early-phase development through clinical supply and all the way to fully scaled-up commercial finished dose form manufacturing in Europe.

Under the terms of this agreement, Catalent will also have access to the facility’s integrated quality control and analytical capabilities with scientific support resources, enabling an end-to-end approach for customers.

“This agreement not only gives Catalent access to spray drying capabilities at Haverhill and its state-of-the-art equipment, but also an experienced and skilled team at the site with expertise in commercial-scale spray dried dispersions, which are frequently used today to overcome the solubility challenges with many new medicines,” said Jonathan Arnold, President of Catalent’s Oral Drug Delivery business unit.

Earlier this year, Catalent announced a $40M investment in its Winchester, Kentucky facility that includes adding commercial-scale spray drying with high-potent handling capabilities, as well as other increases to the site’s capacity and its formulation and controlled-release tablet and capsule manufacturing capabilities.

Niro is a registered trademark of GEA Group (www.gea.com)

Catalent is a leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. 

Related Content

ABB

The Big 6 flowmeter technologies: Where to use them and why

WHITE PAPER — The Big 6 flowmeter technologies: Where to use them and why Flow is one of the most frequently measured process variables throughout industry, and one where the choice in measurement technology is critical. In fact, no single flowmeter…

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Fluidized bed drying and cooling for temperature-sensitive polymers and plastics
CoriolisMaster: The SmartSensor solution
The Big 6 flowmeter technologies: Where to use them and why
Hydrofluoric acid alkylation (HFU) unit optimization
Looking for ways to step up your petrochemical and polymer production?

View More